Decreased maximal cortisol secretion rate in patients with cirrhosis: Relation to disease severity.
Fiche publication
Date publication
juin 2021
Journal
JHEP reports : innovation in hepatology
Auteurs
Membres identifiés du Cancéropôle Est :
Pr DI MARTINO Vincent
Tous les auteurs :
Lovato CM, Thévenot T, Borot S, Di Martino V, Qualls CR, Urban FK, Dorin RI
Lien Pubmed
Résumé
Hepatic enzymes play a major role in the metabolic elimination of cortisol, and reduced rates of cortisol clearance have been consistently observed in patients with chronic liver disease. It is less clear whether there are concomitant abnormalities of adrenocortical function in patients with cirrhosis. In the present study, we sought to assess adrenocortical function in patients with cirrhosis using measures of free cortisol appearance and elimination rates that are independent of serum concentrations of cortisol binding proteins.
Mots clés
ACLF, acute-on-chronic liver failure, ACTH, adrenocorticotrophin, AI, adrenal insufficiency, Adrenal insufficiency, CBG, corticosteroid-binding globulin, CIRCI, critical illness-related corticosteroid insufficiency, CP, Child-Pugh, CPR, cortisol production rate, CRP, C-reactive protein, CRT, corticosteroid replacement therapy, CSR, cortisol secretion rate, CSRbase, basal CSR (before ACTH stimulation), CSRmax, maximal CSR, Computer-assisted numerical analysis, HPA, hypothalamic–pituitary–adrenal, HSD, hydroxysteroid dehydrogenase, Hydrocortisone, INR, international normalised ratio, Liver disease, MCR, metabolic clearance rate, MELD, model for end-stage liver disease, Metabolic clearance rate, PAI, primary adrenal insufficiency, RAI, relative adrenal insufficiency, RCT, randomised clinical trial, SAI, secondary adrenal insufficiency, SCOTCH, Supplemental Corticosteroids in Cirrhotic Hypotensive Patients With Suspicion of Sepsis, STB, standardised beta
Référence
JHEP Rep. 2021 Jun;3(3):100277